RVNC - レバンス・セラピュ―ティクス (Revance Therapeutics Inc.) レバンス・セラピュ―ティクス

 RVNCのチャート


 RVNCの企業情報

symbol RVNC
会社名 Revance Therapeutics Inc (レバンス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 レバンス・セラピューティクス(Revance Therapeutics Inc.)は臨床段階のバイオテクノロジー会社である。同社は美容及び治療的適応症のためのボツリヌス毒素製品の開発、製造及び商業化に従事する。同社のペプチド技術は、注射用ダキシボトリュームトキシンA(RT002)または注射可能RT002及びダキシボチュリントキシンA局所用ゲル(RT001)またはRT001注射剤という2つの治験薬品候補を通じてA型ボツリヌス毒素を送達する。同社はRT002注射剤の臨床開発に従事する。RT002注射剤は生理食塩水ベースの製剤中でボツリヌス毒素 - ペプチド複合体を利用する。RT002注射剤はペプチドは標的筋肉の細胞外構造及び細胞表面受容体と相互作用する。この相互作用は毒素分子を標的部位に制限し、隣接筋肉への広がりを減少させる。同社はグラベラ・ライン、頸部ジストニア及び足底筋膜炎の治療のためのRT002の開発を行う。   レバンス・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。審美及び治療応用のためのボツリヌス毒素製品の開発、製造、商業化に従事。主要製品候補の「RT001」は、独自の技術による注射の必要のないゲルタイプのボツリヌス毒素製品。また、注射タイプの「RT002」は、ボツリヌス毒素の深い浸透により、より長い持続効果が期待される。   Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which provides an integrated smart payment solution that supports aesthetic practice management, practice economics and practice loyalty. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences.
本社所在地 7555 Gateway Boulevard Newark CA 94560 USA
代表者氏名 Angus Charles Russell アンガス・チャールズ・ラッセル
代表者役職名 Independent Chairman of the Board
電話番号 +1 510-742-3400
設立年月日 36373
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 134人
url www.revance.com
nasdaq_url https://www.nasdaq.com/symbol/rvnc
adr_tso
EBITDA EBITDA(百万ドル) -132.59800
終値(lastsale) 23.57
時価総額(marketcap) 870626090.87
時価総額 時価総額(百万ドル) 884.66250
売上高 売上高(百万ドル) 0.99100
企業価値(EV) 企業価値(EV)(百万ドル) 650.92850
当期純利益 当期純利益(百万ドル) -135.67500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Revance Therapeutics Inc revenues increased from $150K to $879K. Net loss increased 28% to $69.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling and Adminstative balance increase of 75% to $21.8M (expense) Research_Development balance increase of 18% to $41.3M (expense).

 RVNCのテクニカル分析


 RVNCのニュース

   Dermal Fillers Market to Hit USD 6.28 Billion with 10.8% CAGR by 2028; Increasing Adoption of Painless Facial Treatment to Augment Market Growth: Fortune Business Insights  2021/09/27 10:34:00 Intrado Digital Media
Top Players Covered in the Dermal Fillers Market Research Report Are Anika Therapeutics Inc. (Massachusetts, U.S.), Suneva Medical (California, U.S.), Prollenium Medical Technologies (Toronto, Canada), DR. Korman (Kiryat Bialik, Isreal), SCULPT Luxury Dermal Fillers LTD. (U.K), Bioxis Pharmaceuticals (Lyon, France), BIOPLUS CO. LTD. (South Korea), Sun Pharmaceutical Industries Ltd (Mumbai, India), Sinclair Pharma (London, U.K.), Galderma (Lausanne, Switzerland), Merz Pharma (Frankfurt, Germany), Revance Therapeutics Inc. (California, U.S.), ALLERGAN (Dublin, Ireland) and other key market players. Top Players Covered in the Dermal Fillers Market Research Report Are Anika Therapeutics Inc. (Massachusetts, U.S.), Suneva Medical (California, U.S.), Prollenium Medical Technologies (Toronto, Canada), DR. Korman (Kiryat Bialik, Isreal), SCULPT Luxury Dermal Fillers LTD. (U.K), Bioxis Pharmaceuticals (Lyon, France), BIOPLUS CO. LTD. (South Korea), Sun Pharmaceutical Industries Ltd (Mumbai, India), Sinclair Pharma (London, U.
   Revance To Present Results From Phase 3 Trial Of DaxibotulinumtoxinA On Cervical Dystonia  2021/09/16 12:43:49 Business Insider Markets
(RTTNews) - Revance Therapeutics Inc. (RVNC) said Thursday that it will present results from its ASPEN-1 Phase 3 clinical trial evaluating the efficacy, duration of effect and safety of DaxibotulinumtoxinA for Injection, for the treatment of cervical dystonia in adults, showing a meaningful reduction in signs and symptoms associated with
   Revance Therapeutics: Frowning At The FDA  2021/08/15 17:39:09 Seeking Alpha
   Dermal Fillers Market Size | Hit USD 6.25 Billion by 2028 and Exhibit 10.8% CAGR  2021/08/10 08:56:00 Intrado Digital Media
Top Players Covered in the Dermal Fillers Market Research Report Are Anika Therapeutics Inc. (Massachusetts, U.S.), Suneva Medical (California, U.S.), Prollenium Medical Technologies (Toronto, Canada), DR. Korman (Kiryat Bialik, Isreal), SCULPT Luxury Dermal Fillers LTD. (U.K), Bioxis Pharmaceuticals (Lyon, France), BIOPLUS CO. LTD. (South Korea), Sun Pharmaceutical Industries Ltd (Mumbai, India), Sinclair Pharma (London, U.K.), Galderma (Lausanne, Switzerland), Merz Pharma (Frankfurt, Germany), Revance Therapeutics Inc. (California, U.S.), ALLERGAN (Dublin, Ireland) and other key market players. Top Players Covered in the Dermal Fillers Market Research Report Are Anika Therapeutics Inc. (Massachusetts, U.S.), Suneva Medical (California, U.S.), Prollenium Medical Technologies (Toronto, Canada), DR. Korman (Kiryat Bialik, Isreal), SCULPT Luxury Dermal Fillers LTD. (U.K), Bioxis Pharmaceuticals (Lyon, France), BIOPLUS CO. LTD. (South Korea), Sun Pharmaceutical Industries Ltd (Mumbai, India), Sinclair Pharma (London, U.
   Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2021 Results - Earnings Call Transcript  2021/08/08 19:02:05 Seeking Alpha
   Global Facial Rejuvenation Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Merz Pharmaceuticals, Lumenis, Revance Therapeutics, Biopolymer, Speciality European Pharma, Mentor Worldwide, Alma Lasers, Anika Therapeutics, Contura, Cynosure, Fibrocell, Galderma  2021/07/24 00:31:59 Jumbo News
The report on Global Facial Rejuvenation Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition []
   Revance Therapeutics Stock Appears To Be Possible Value Trap  2021/07/10 17:00:09 GuruFocus
Related Stocks: RVNC ,
   Spasticity Market : Industry Analysis, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight| Osmotica Pharmaceuticals, Revance Therapeutics, Bionorica SE and Others.  2021/07/07 22:18:02 AB Newswire
   Botulinum Toxin Market 2026 | Will Reach 8,309.0 Million by 2026, Exhibiting a CAGR of 8.0%  2021/07/05 10:16:00 Intrado Digital Media
Top Players Covered in the Botulinum Toxin Market Research Report Are Revance Therapeutics, Inc. (California, U.S.), Lanzhou Institute of Biological Products Co., Ltd. (Gansu, China), USWM, LLC. (Kentucky, U.S.), Merz Pharma (Frankfurt, Germany), HUGEL, Inc. (Seoul, Republic of Korea), Galderma (Lausanne, Switzerland), Medytox (Cheongju-si, South Korea), Allergan (Dublin, Ireland) and other key market players. Top Players Covered in the Botulinum Toxin Market Research Report Are Revance Therapeutics, Inc. (California, U.S.), Lanzhou Institute of Biological Products Co., Ltd. (Gansu, China), USWM, LLC. (Kentucky, U.S.), Merz Pharma (Frankfurt, Germany), HUGEL, Inc. (Seoul, Republic of Korea), Galderma (Lausanne, Switzerland), Medytox (Cheongju-si, South Korea), Allergan (Dublin, Ireland) and other key market players.
   Looking Into Revance Therapeutics''s Return On Capital Employed - Stocks News Feed  2021/06/24 13:50:45 Stocks News Feed
Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $13.30 million. Earnings fell to a loss of $70.01 million, resulting in a 10.21% decrease from last quarter. Revance Therapeutics collected $11.13 million in revenue during Q4, but reported earnings showed a $77.97 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax Read More »Looking Into Revance Therapeuticss Return On Capital Employed
   Global Facial Rejuvenation Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Merz Pharmaceuticals, Lumenis, Revance Therapeutics, Biopolymer, Speciality European Pharma, Mentor Worldwide, Alma Lasers, Anika Therapeutics, Contura, Cynosure, Fibrocell, Galderma  2021/07/24 00:31:59 Jumbo News
The report on Global Facial Rejuvenation Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition []
   Revance Therapeutics Stock Appears To Be Possible Value Trap  2021/07/10 17:00:09 GuruFocus
Related Stocks: RVNC ,
   Spasticity Market : Industry Analysis, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight| Osmotica Pharmaceuticals, Revance Therapeutics, Bionorica SE and Others.  2021/07/07 22:18:02 AB Newswire
   Botulinum Toxin Market 2026 | Will Reach 8,309.0 Million by 2026, Exhibiting a CAGR of 8.0%  2021/07/05 10:16:00 Intrado Digital Media
Top Players Covered in the Botulinum Toxin Market Research Report Are Revance Therapeutics, Inc. (California, U.S.), Lanzhou Institute of Biological Products Co., Ltd. (Gansu, China), USWM, LLC. (Kentucky, U.S.), Merz Pharma (Frankfurt, Germany), HUGEL, Inc. (Seoul, Republic of Korea), Galderma (Lausanne, Switzerland), Medytox (Cheongju-si, South Korea), Allergan (Dublin, Ireland) and other key market players. Top Players Covered in the Botulinum Toxin Market Research Report Are Revance Therapeutics, Inc. (California, U.S.), Lanzhou Institute of Biological Products Co., Ltd. (Gansu, China), USWM, LLC. (Kentucky, U.S.), Merz Pharma (Frankfurt, Germany), HUGEL, Inc. (Seoul, Republic of Korea), Galderma (Lausanne, Switzerland), Medytox (Cheongju-si, South Korea), Allergan (Dublin, Ireland) and other key market players.
   Looking Into Revance Therapeutics''s Return On Capital Employed - Stocks News Feed  2021/06/24 13:50:45 Stocks News Feed
Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $13.30 million. Earnings fell to a loss of $70.01 million, resulting in a 10.21% decrease from last quarter. Revance Therapeutics collected $11.13 million in revenue during Q4, but reported earnings showed a $77.97 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax Read More »Looking Into Revance Therapeuticss Return On Capital Employed

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 レバンス・セラピュ―ティクス RVNC Revance Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)